Alzheimer’s Disease Assessment Panel
Tau–Amyloid Profiling For Preventing Cognitive Insight
Overview
The Alzheimer’s Disease Assessment Panel equips clinicians with a direct biological window into early Alzheimer’s-related brain pathology using the FDA-cleared Lumipulse® pTau217/Aβ1-42 blood test.
This panel focuses exclusively on current neurodegenerative activity by evaluating circulating biomarkers associated with amyloid plaque accumulation and neuronal injury, enabling earlier risk identification long before visible cognitive decline occurs.
Unlike symptom-based screening tools, this assessment provides objective biochemical evidence of Alzheimer’s pathology, empowering proactive, preventive, and precision-guided cognitive care.
What This Test Covers
FDA-Cleared Lumipulse® pTau217 / Aβ1-42 Plasma Ratio Test
This panel includes the first FDA-cleared blood-based biomarker test for evaluating Alzheimer’s disease.
It measures two critical neurodegenerative biomarkers:
- Phosphorylated Tau-217 (pTau217) – Reflects neuronal injury and tau pathology
- β-Amyloid 1-42 (Aβ1-42) – Reflects amyloid plaque accumulation in the brain
The pTau217 / Aβ1-42 ratio identifies biological changes associated with amyloid pathology that often appear years before clinical memory symptoms become evident, enabling early awareness and monitoring.
Quantitative Biomarker Reporting
The report provides:
- Calculated pTau217/Aβ1-42 ratio
- Results reported in standardized laboratory units
This quantitative format allows clinicians to track biological trends and monitor disease progression over time.
Health Support Insights
- Cognitive Exercise Training Evidence-informed activities that support neuroplasticity, memory, and long-term brain resilience.
- Nutritional Insights Targeted nutrition insights to support amyloid clearance, mitochondrial health, and inflammation balance.
- Lifestyle Strategies Key modifiable factors including sleep, stress, metabolic health, and cardiovascular function.
- Supplement Insights Evidence-based supplement considerations aligned with biomarker findings.
- Labs to Consider Select laboratory markers to further personalize clinical care.
Why It Matters
Alzheimer’s does not begin with memory loss, it begins silently, years before symptoms ever surface. By the time cognitive changes are noticeable, significant and often irreversible neurological damage has already occurred.
With this assessment, clinicians can
- Reveal hidden neurodegenerative activity before clinical decline
- Guide patients with objective, lab-validated evidence instead of uncertainty
- Personalize prevention strategies with measurable biological data
- Build patient trust through clear, data-driven conversations
- Position their practice as a leader in advanced cognitive longevity care
Who Should Take This Test
Designed for
Physicians and neurologists
Physicians and neurologists
Functional & integrative medicine practitioners
Preventive, longevity, and cognitive health clinics
Clinicians managing patients with memory concerns or a family history of dementia
Ideal for practices delivering precision-guided, preventive brain health care
What You’ll Receive
Comprehensive Report
• FDA-cleared pTau217 / Aβ1-42 biomarker results
• Quantitative lab values and ratio interpretation
Personalized Insights
Clinically relevant insights across cognitive, nutrition, lifestyle, supplement and lab insights.
Provider Portal Access
Secure digital access to the ExtendingME Provider Portal for test ordering and result tracking.
Turnaround Time
Results will be available approximately 2 weeks from the receipt of the sample and will be securely delivered through the Provider Portal, allowing efficient review and patient follow-up.
Collection Method
ExtendingME kits include all necessary self-collection devices for non-invasive, at-home saliva collection, making it easy to deliver real-time, data-driven healthcare solutions without the need for lab visits.
